Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

  • Sort by:
  • Browse by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 84
THE EMERGING POTENTIAL FOR HIV CURE FOR INFANTS, CHILDREN, AND ADULTS
Jintanat Ananworanich
US Military HIV Research Program, Thai Red Cross, Bethesda, MD, USA
from CROI 2017 on February 14, 2017 8:30 AM-9:30 AM
ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV
Carl H June
University of Pennsylvania, Philadelphia, PA, USA
from CROI 2017 on February 14, 2017 8:30 AM-9:30 AM
RANDOMIZED TRIAL OF LEEP VS CRYOTHERAPY TO TREAT CIN2/3 IN HIV-INFECTED WOMEN
Sharon A Greene
University of Washington, Seattle, WA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
NATURAL HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA-2 AMONG HIV-INFECTED WOMEN
Kate Michel
Georgetown University, Washington, DC, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
INTEGRATION OF POSTNATAL SERVICES IMPROVES MCH AND ART OUTCOMES: A RANDOMISED TRIAL
Landon Myer
University of Cape Town, Cape Town, South Africa
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
ADVERSE BIRTH OUTCOMES DIFFER BY ART REGIMEN FROM CONCEPTION IN BOTSWANA
Rebecca Zash
Beth Israel Deaconess Medical Center, Boston, MA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
EFFECT OF POINT-OF-CARE TESTING ON ANTIRETROVIRAL-THERAPY INITIATION RATES IN INFANTS
Ilesh Jani
Instituto Nacional de Saude, Maputo, Mozambique
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
TREATMENT OF ACUTE HIV INFECTION IN NEONATES
Louise Kuhn
Columbia University, New York, NY, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
RAPID DECLINE OF TOTAL HIV DNA IN CHILDREN STARTING ART WITHIN 8 DAYS OF BIRTH
Kirsten Abigail Veldsman
Stellenbosch University, Parow, South Africa
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
LOPINAVIR/RITONAVIR 1:1 SUPER-BOOSTING OVERCOMES RIFAMPICIN INTERACTIONS IN CHILDREN
Helena Rabie
University of Stellenbosch, Cape Town, South Africa
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
QUATERNARY CONFIGURATION OF THE FUNCTIONAL CD4-BINDING SITE IN THE HIV-1 ENV TRIMER
Qingbo Liu
NIH, Bethesda, MD, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
EARLY CYTOPLASMIC UNCOATING IS NECESSARY FOR INFECTIVITY OF HIV-1
João I Mamede
Northwestern University, Chicago, IL, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
ECCENTRIC VIRAL GENOMIC RNA AND INTEGRASE ARE PREMATURELY DEGRADED IN TARGET CELLS
Sebla B Kutluay
Washington University in St. Louis, St. Louis, MO, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
DYNAMICS OF NUCLEAR ENVELOPE ASSOCIATION AND NUCLEAR IMPORT OF HIV-1 COMPLEXES
Ryan C Burdick
National Cancer Institute, Frederick, MD, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
CYPA REGULATES HIV-1 ACCESS TO AN FG-GUIDED NUCLEAR ENTRY PATHWAY
Guangai Xue
National Cancer Institute, Frederick , MD, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
A COMPREHENSIVE CRISPR SCREEN IDENTIFIES NOVEL HIV RESTRICTION FACTORS
Molly Ohainle
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
A RETROTRANSPOSED ESCRT-III FACTOR BLOCKS HIV-1 BUDDING WITHOUT INDUCING CYTOTOXICITY
Lara Rheinemann
University of Utah, Salt Lake City, UT, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
DESIGNED PROTEINS INDUCE THE FORMATION OF NANOCAGE-CONTAINING EXTRACELLULAR VESICLES
Joerg Votteler
University of Utah, Salt Lake City, UT, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
HIV INCIDENCE, PREVALENCE, AND UNDIAGNOSED INFECTIONS IN MEN WHO HAVE SEX WITH MEN
Sonia Singh
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
VIRAL-LOAD DYNAMICS AMONG PERSONS WITH DIAGNOSED HIV: UNITED STATES, 2014
Nicole Crepaz
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
TIME SPENT WITH HIV VIRAL LOAD >1500 COPIES/mL AMONG PATIENTS IN HIV CARE, 2000-2014
Kate Buchacz
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
A RANDOMIZED TRIAL OF NOVEL STRATEGIES TO INCENTIVIZE HIV TESTING AMONG MEN IN UGANDA
Gabriel Chamie
University of California, San Francisco, San Francisco, CA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
COMBINATION HIV PREVENTION AND HIV INCIDENCE IN RAKAI, UGANDA
Mary K Grabowski
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
NAMIBIA PILOTS SENTINEL POPULATION SURVEILLANCE OF HIV INCIDENCE AND VIRAL SUPRESSION
Sadhna V Patel
U.S. Centers for Disease Control and Prevention, Atlanta, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
SOCIAL NETWORKS AND HIV PREVALENCE IN KENYA IN THE SEARCH STUDY
Wenjing Zheng
University of California, Berkeley, Berkeley, CA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
HIGH RATE OF DISEASE PROGRESSION IN UNTREATED HIV-2 INFECTION
Joakim Esbjörnsson
University of Oxford, Oxford, United Kingdom
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
DISCOVERY OF NOVEL POTENT HIV CAPSID INHIBITORS WITH LONG-ACTING POTENTIAL
Winston C Tse
Gilead Sciences, Foster City, CA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
HUMAN CONFIRMATION OF ORAL DOSE REDUCTION POTENTIAL OF NANOPARTICLE ARV FORMULATIONS
Andrew Owen
University of Liverpool, Liverpool, Merseyside, United Kingdom
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
CLINICAL PHARMACOLOGY OF THE HIV INTEGRASE STRAND TRANSFER INHIBITOR BICTEGRAVIR
Joseph M. Custodio
Gilead Science, Foster city, CA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
RANDOMIZED TRIAL OF BICTEGRAVIR OR DOLUTEGRAVIR WITH FTC/TAF FOR INITIAL HIV THERAPY
Paul E Sax
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
PATHWAYS OF RESISTANCE IN SUBJECTS FAILING DOLUTEGRAVIR MONOTHERAPY
José L Blanco
Hospital Clinic, Barcelona, Outside USA or Canada, Spain
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
PREVALENCE AND IMPACT OF PRETREATMENT DRUG RESISTANCE IN THE ANRS 12249 TASP TRIAL
Anne Derache
Africa Health Research Institute, Mtubatuba, South Africa
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
PHASE III SWORD 1&2: SWITCH TO DTG+RPV MAINTAINS VIROLOGIC SUPPRESSION THROUGH 48 WKS
Josep M Llibre
Univ Hosp Germans Trias, Badalona, Barcelona, Spain
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
DORAVIRINE IS NON-INFERIOR TO DARUNAVIR/R IN PHASE 3 TREATMENT-NAÏVE TRIAL AT WEEK 48
Kathleen Squires
Thomas Jefferson University, Philadelphia, PA, USA
from CROI 2017 on February 14, 2017 10:00 AM-12:00 PM
DISCUSSION OF ORAL ABSTRACT SESSION 2 – CRITICAL ISSUES IN WOMEN'S HEALTH, MTCT, AND HIV TREATMENT IN CHILDREN
CHAIR
Elaine Abrams
Columbia University, New York, NY, USA
OA2: RANDOMIZED TRIAL OF LEEP VS CRYOTHERAPY TO TREAT CIN2/3 IN HIV-INFECTED WOMEN
Sharon Greene
Univ of Washington, Seattle, WA, USA
OA2: INTEGRATION OF POSTNATAL SERVICES IMPROVES MCH AND ART OUTCOMES: A RANDOMISED TRIAL
Landon Myer
Univ of Cape Town, Cape Town, South Africa
OA2: ADVERSE BIRTH OUTCOMES DIFFER BY ART REGIMEN FROM CONCEPTION IN BOTSWANA
Rebecca Zash
Beth Israel Deaconess Med Cntr, Boston, MA, USA
OA2: EFFECT OF POINT-OF-CARE TESTING ON ANTIRETROVIRAL-THERAPY INITIATION RATES IN INFANTS
Ilesh Jani
Instituto Nacional de Saude, Maputo, Mozambique
OA2: TREATMENT OF ACUTE HIV INFECTION IN NEONATES
Louise Kuhn
Columbia Univ, New York, NY, USA
from CROI 2017 on February 14, 2017 12:15 PM-1:15 PM
DISCUSSION OF ORAL ABSTRACT SESSION 3 – HIDING IN PLAIN SIGHT: DISCOVERING THE UNDIAGNOSED AND UNDERTREATED HIV EPIDEMIC
OA3: COMBINATION HIV PREVENTION AND HIV INCIDENCE IN RAKAI, UGANDA
Mary Grabowski
The Johns Hopkins Univ, Baltimore, MD, USA
CHAIR
Kevin M. De Cock
Centers for Disease Control and Prevention, Nairobi, Kenya
OA3: HIV INCIDENCE, PREVALENCE, AND UNDIAGNOSED INFECTIONS IN MEN WHO HAVE SEX WITH MEN
Sonia Singh
CDC, Atlanta, GA, USA
OA3: VIRAL-LOAD DYNAMICS AMONG PERSONS WITH DIAGNOSED HIV: UNITED STATES, 2014
Nicole Crepaz
CDC, Atlanta, GA, USA
from CROI 2017 on February 14, 2017 12:15 PM-1:15 PM
DISCUSSION OF POSTER SESSION – EMERGING VIRUSES: ZIKA VIRUS AND THEMED DISCUSSION 17 – EMERGING VIRUSES: THE ZIKA VIRUS
CHAIR
David Thomas
Johns Hopkins School of Medicine, Baltimore, MD, USA
TD17: ZIKA VIRUS PERSISTENCE IN BODY FLUIDS
Gabriela Paz-Bailey
CDC, Atlanta, GA, USA
TD17: NEUROLOGIC CONSEQUENCES OF POSTNATAL ZIKA VIRUS INFECTION IN INFANTS
Maud Mavigner
Emory Univ, Atlanta, GA, USA
TD17: ZIKA VIRUS PROTECTION BY A SINGLE LOW-DOSE NUCLEOSIDE-MODIFIED MRNA VACCINATION
Michael Hogan
Univ of Pennsylvania, Philadelphia, PA, USA
from CROI 2017 on February 14, 2017 12:15 PM-1:15 PM
THEMED DISCUSSION LEADER
Nicole Frahm
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
LYMPH NODE HIV-SPECIFIC CXCR5+ CTLs ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL
Zaza Ndhlovu
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
RESIDENT MEMORY CD8+ T CELLS FORM THE FRONT-LINE DEFENSE IN HIV-INFECTED LYMPH NODES
Marcus Buggert
University of Pennsylvania, Philadelphia, PA, USA
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
HIV-1 ESCAPE FROM CD8+ CYTOTOXIC T-LYMPHOCYTES DEFINED AT CLONAL RESOLUTION
Aleksandr Gorin
University of California, Los Angeles, Los Angeles, USA
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
INVESTIGATING THE ROLE OF TCR STRUCTURE IN FUNCTIONAL ACTIVITY OF HIV-SPECIFIC CTLS
Nina Campbell Flerin
Albert Einstein College of Medicine, Bronx, NY, USA
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
HIV-SPECIFIC CD8 T CELLS IN PERSONS TREATED IN FIEBIG I ACUTE INFECTION WHO STOP ART
Hiroshi Takata
US Military HIV Research Program; HJF, Silver Spring, MD, USA
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
QUESTIONS AND ANSWERS
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
THEMED DISCUSSION LEADER
Andrea Howard
Columbia University, New York, NY, USA
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
MIGRATION, GENDER, AND HIV INCIDENCE IN RAKAI, UGANDA
Oluwasolape M Olawore
Johns Hopkins University, Baltimore, MD, USA
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
OUTCOMES ALONG THE HIV CARE CONTINUUM AMONG UNDOCUMENTED IMMIGRANTS IN CLINICAL CARE
Jonathan Ross
Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, USA
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
IMMIGRANTS AND BOTSWANA'S ART PROGRAM: POTENTIAL BARRIERS TO EPIDEMIC CONTROL
Tafireyi Marukutira
Macfarlane Burnet Inst For Med Res & Public Health, Melbourne, Australia
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
CASCADE OF CARE OF HIV SEROCONVERTERS IN THE CONTEXT OF UNIVERSAL “TEST AND TREAT”
Joseph Larmarange
Institut de Recherche pour le Développement (IRD), Paris, France
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
QUESTIONS AND ANSWERS
from CROI 2017 on February 14, 2017 1:30 PM-2:30 PM
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 84